Similarly, the use of SGLT2 inhibitors was not associated with a significant increase in the risk of hypoglycemic events (RR = 1.01, 95% CI: 0.80–1.29, I2 = 0%; Figure 5b), UTI (RR = 1.13, 95% CI: 0.99–1.29, I2 = 1%; Figure 5c), or AKI (RR = 0.94, 95% CI: 0.83–1.06, I2 = 0%; Figure 5d). This evidence concerns the gene SLC5A2 and acute kidney injury.